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Introduction
Acute myeloid leukemia (AML) is a clonal hematological disorder in which somatically acquired genetic alterations in hematopoietic stem/progenitor cells (HSPCs) disturb their growth and differentiation. Chromosomal abnormalities or specific gene mutations are used in the risk classification of AML as prognostic biomarkers. In addition, distinct gene expression signatures have been utilized to identify the prognostic subclasses of AML. 1 Among these stratified groups, aberrant expression of ecotropic viral integration site 1 (Evi1) occurs in approximately 5-10% of de novo AML patients and defines one of the largest clusters in AML. 2-5 EVI1 gene is located on chromosome 3q26 and its inappropriate expression is often caused by 3q abnormalities such as inv(3)(q21q26.2) or t(3;3)(q21;q26.2). 6 According to the World Health Organization classification, AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is associated with normal or elevated platelet counts and shows increased atypical bone marrow (BM) megakaryocytes and associated multilineage dysplasia. 7 Furthermore, monosomy 7 and 11q23 translocations involving the mixed lineage leukemia (MLL) gene are frequently accompanied by deregulated expression of Evi1. 2,4,5 Regardless of cytogenetics, high Evi1 expression predicts adverse outcome mainly due to a poor therapeutic response.
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Evi1 is a transcription factor highly expressed in hematopoietic stem cells (HSCs) and is crucial for their self-renewal capacity. 9 Meanwhile, Evi1 exerts diverse oncogenic functions by suppressing transforming growth factor-β signaling, 10 inhibiting c-Jun N-terminal kinase, 11 inducing activator protein-1 activity, 12 and activating AKT/mTOR signaling through PTEN repression. 13 Moreover, Evi1 physically interacts with multiple components of epigenetic machineries, 14- In this study, we sought to clarify specific molecular features of AML with high Evi1 expression using the mouse model of Evi1 leukemia that we previously established. 13, 21 By analyzing gene expression data of AML patients, we first revealed that the expression of ITGA2B (CD41), a megakaryocytic differentiation marker, positively correlates with that of EVI1. In Evi1 leukemia mice, a subpopulation of leukemia cells did express CD41. Importantly, CD41 + Evi1 leukemia cells had more efficient leukemia-initiating capacity (LIC) than CD41 − cells. In addition, Mpl, the receptor for thrombopoietin (THPO), was predominantly expressed in the CD41 + cells, and stimulation by THPO supported their growth and survival via upregulation of BCL-xL. These results suggest that the THPO/MPL pathway can be critical for the progression of Evi1 leukemia as a cell-extrinsic factor.
Methods

Vectors
Retroviral vectors used for transformation of primary murine BM cells were as follows:
pMYs-mouse Evi1-IRES-GFP 13 and pMSCV-MLL-ENL-IRES-GFP.
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The pMYs-mouse Evi1-IRES-GFP vector was also used for generating Evi1 leukemia mice.
Murine Evi1 gene used in this study encodes the Evi1 isoform of Mds1 and Evi1 complex locus (Mecom), and its sequence information has been registered as an accession number JQ665270.1 in GenBank.
Generation of Evi1 leukemia mice
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Evi1 leukemia mice were generated as described previously. 13, 21 In brief, BM mononuclear cells (BM-MNCs) isolated from C57BL/6 mice after treatment with 5-fluorouracil (5-FU) were retrovirally transduced with Evi1. The infected cells were injected through the tail vein into sublethally irradiated (5.25 Gy) syngeneic recipient mice. All animal experiments were approved by the University of Tokyo Institutional
Animal Care and Use Committee.
Flow cytometry
Cell sorting and analysis were performed by using FACSAriaII, FACSAriaIII, and LSRII (all from BD Biosciences, San Jose, CA, USA). The data were analyzed using 
Results
Expression of ITGA2B correlates with that of EVI1 in human AML
To identify cell surface molecules specific to Evi1-overexpresssing leukemia cells, we analyzed two sets of microarray data. First, gene expression profiles consisting of 460 human AML samples 23 were divided into EVI1-high (30 cases) and EVI1-low (430 cases) groups, and 400 genes highly expressed in the EVI1-high group were extracted (supplemental Table 1 ). To narrow down the candidate genes, we selected 2,199 genes repressed by Evi1 deletion using the gene expression profiles of KSL derived from Evi1
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 7 wild-type and cKO mice (supplemental Table 2 ). 9 We then identified 11 cell surface molecules among 42 genes commonly found in these lists ( Figure 1A , Table 1, and   supplemental Table 3 ). These candidate genes contained several megakaryocyte/platelet lineage markers such as ITGA2B (CD41), ITGB3 (CD61), PEAR1, SELP, and MPL.
Analysis of another set of AML microarray data 24 confirmed that the expression of ITGA2B, MPL, and SELP was correlated with that of EVI1 (supplemental Table 4 ). In addition, Gene Set Enrichment Analysis (GSEA) revealed that molecular signatures relevant to platelet function and integrin αIIbβ3 (CD41/CD61) signaling were significantly enriched in the EVI1-high group ( Figure 1B -E). These results indicate that the expression of megakaryocytic markers, in particular ITGA2B, strongly correlates with that of EVI1 in human AML.
Expression levels of candidate megakaryocytic marker genes were comparable between EVI1-high cases with 3q abnormalities and those without 3q abnormalities ( Figure 1F and supplemental Figure 1A ). When compared with MLL-rearranged cases without EVI1 expression, those with EVI1 overexpression showed higher expression of ITGA2B, MPL, and PEAR1 ( Figure 1G and supplemental Figure 1B ). These results suggested that expression of megakaryocytic marker genes would mark EVI1-positive AML cases irrespective of cytogenetic abnormalities.
Evi1-overexpressing cells express CD41
To confirm the association between CD41 and Evi1, we next examined CD41 
CD41 + Evi1 leukemia cells have higher LIC than CD41 − cells
Next, we checked CD41 expression in the mouse model of Evi1 leukemia. 13, 21 As shown in Figure 3A , CD41 was distinctly expressed in BM and spleen (SP) cells of Evi1 leukemia mice. CD41 + cells expressed immature markers such as c-kit and CD150 more frequently than CD41 − cells ( Figure 3B ). In contrast, Gr- Figure 3C ).
Morphological analysis revealed that CD41 + cells contained myeloblasts with high nucleus/cytoplasm ratio more abundantly than CD41 − cells ( Figure 3D ). In a colony-forming assay, CD41 + cells generated larger colonies and showed higher colony-forming capacity than CD41 − cells ( Figure 3E ). There was no significant difference between CD41 + and CD41 − cells in the cell cycle status ( Figure 3F ). On the other hand, an apoptotic rate in CD41 + cells were significantly lower than in CD41 
Mpl is predominantly expressed in CD41 + Evi1 leukemia cells
As shown in Table 1 , expression of several megakaryocytic markers correlated with that 
To test whether THPO/MPL signaling is important for the progression of Evi1
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latency than those transplanted with CD41 + cells ( Figure 3H is counteracted by Evi1 in our mouse model. However, we cannot exclude another possibility that expression of Mpl and Gata1 is controlled by a disease stage-specific manner in the process of developing Evi1 leukemia. As shown in Figure 3H , leukemic
symptoms were emerged after a relatively longer latency (over 150 days) in primary transplantation assays, speculating that disease phenotype in earlier time points after transplantation may be different from that in the later leukemic stage. Therefore, Figure 3H) , and showed the equivalent homing capacity to BM and SP to that of CD41 − cells (supplemental Figure 3) . In addition, we found that the progression of AML was not delayed when Evi1 leukemia cells in which surface CD41 expression was partially interfered by an
Itga2b-knockdown vector were transplanted into mice (data not shown). Thus, CD41/CD61 signaling might be dispensable for proliferation or homing of Evi1 leukemia cells in vivo.
Several clinical studies reported that CD41 or CD61 expression is detected by FACS or immunohistochemistry in a subset of AML specimens with 3q
abnormalities. 46-50 Therefore, we finally examined CD41 expression by FACS using four primary AML samples, one carrying a t(3;3) translocation and the others carrying an MLL-rearrangement. Among them, CD34 + cells derived from the t(3;3) patient and one MLL-rearranged patient more frequently expressed CD41 than those from the others (supplemental Figure 10A) . Interestingly, CD34 + cells of these two patients clearly expressed EVI1 (supplemental Figure 10B-C) . Further investigation using more clinical samples with EVI1 expression will be needed to confirm the relationship between Evi1 and CD41. Genes localized at the cell surface membrane were extracted from the 42 candidate genes identified in Figure 1A . Fold changes calculated from the microarray data of human AML samples are shown.
* These genes represent surface markers of megakaryocyte and platelet lineage. 
